Literature DB >> 11205157

Evidence for enhanced neuro-inflammatory processes in neurodegenerative diseases and the action of nitrones as potential therapeutics.

R A Floyd1, K Hensley, G Bing.   

Abstract

A brief review is presented on observations leading to the current notions regarding neuro-inflammatory processes. The greatest focus is on Alzheimer's disease (AD) since this is where the most convincing data has been obtained. A brief summary of observations on the neuroprotective action of alpha-phenyl-tert-butyl-nitrone (PBN) as well as results of research designed to understand its mechanism of action is presented. We hypothesize that the mechanism of action of PBN involves inhibition of signal transduction processes, which are involved in the upregulation of genes mediated by pro-inflammatory cytokines and H2O2 that cause formation of toxic gene products. Results from recent experiments on Kainic acid (KA) mediated brain damage are provided to suggest the validity of the in vivo action of PBN to inhibit neuro-inflammatory processes. The accumulating scientific facts are helping to provide concepts that may become the basis for novel therapeutic approaches to the treatment of several neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11205157     DOI: 10.1007/978-3-7091-6301-6_28

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  14 in total

1.  Interleukin-1beta-induced brain injury and neurobehavioral dysfunctions in juvenile rats can be attenuated by alpha-phenyl-n-tert-butyl-nitrone.

Authors:  L W Fan; L T Tien; B Zheng; Y Pang; P G Rhodes; Z Cai
Journal:  Neuroscience       Date:  2010-03-24       Impact factor: 3.590

Review 2.  Nitrones as therapeutics.

Authors:  Robert A Floyd; Richard D Kopke; Chul-Hee Choi; Steven B Foster; Sabrina Doblas; Rheal A Towner
Journal:  Free Radic Biol Med       Date:  2008-08-29       Impact factor: 7.376

Review 3.  Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines.

Authors:  Robert A Floyd; Hugo C Castro Faria Neto; Guy A Zimmerman; Kenneth Hensley; Rheal A Towner
Journal:  Free Radic Biol Med       Date:  2013-02-16       Impact factor: 7.376

Review 4.  Potential implication of the chemical properties and bioactivity of nitrone spin traps for therapeutics.

Authors:  Frederick A Villamena; Amlan Das; Kevin M Nash
Journal:  Future Med Chem       Date:  2012-06       Impact factor: 3.808

Review 5.  Nitrone-related therapeutics: potential of NXY-059 for the treatment of acute ischaemic stroke.

Authors:  Kirk R Maples; A Richard Green; Robert A Floyd
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 6.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

7.  alpha-Phenyl-n-tert-butyl-nitrone attenuates lipopolysaccharide-induced brain injury and improves neurological reflexes and early sensorimotor behavioral performance in juvenile rats.

Authors:  Lir-Wan Fan; Ruei-Feng Chen; Helen J Mitchell; Rick C S Lin; Kimberly L Simpson; Philip G Rhodes; Zhengwei Cai
Journal:  J Neurosci Res       Date:  2008-12       Impact factor: 4.164

8.  Antioxidants have a rapid and long-lasting effect on neuritic abnormalities in APP:PS1 mice.

Authors:  Monica Garcia-Alloza; Laura A Borrelli; Bradley T Hyman; Brian J Bacskai
Journal:  Neurobiol Aging       Date:  2009-01-04       Impact factor: 4.673

9.  Interleukin-1beta-induced brain injury in the neonatal rat can be ameliorated by alpha-phenyl-n-tert-butyl-nitrone.

Authors:  Lir-Wan Fan; Helen J Mitchell; Lu-Tai Tien; Philip G Rhodes; Zhengwei Cai
Journal:  Exp Neurol       Date:  2009-08-13       Impact factor: 5.330

10.  Alpha-Phenyl-n-tert-butyl-nitrone attenuates lipopolysaccharide-induced neuronal injury in the neonatal rat brain.

Authors:  L-W Fan; H J Mitchell; P G Rhodes; Z Cai
Journal:  Neuroscience       Date:  2007-11-29       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.